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The solid-state form of an active pharmaceutical ingredient (API) in an oral dosage form plays an impor-
tant role in determining the dissolution rate of the API. As the solid-state form can change during disso-
lution, there is a need to monitor the oral dosage form during dissolution testing. Coherent anti-Stokes
Raman scattering (CARS) microscopy provides rapid, spectrally selective imaging to monitor the oral dos-
age form during dissolution. In this study, in situ CARS microscopy was combined with inline UV absorp-
tion spectroscopy to monitor the solid-state change in oral dosage forms containing theophylline
anhydrate undergoing dissolution and to correlate the solid-state change with a change in dissolution
rate. The results from in situ CARS microscopy showed that theophylline anhydrate converted to theoph-
ylline monohydrate during dissolution resulting in a reduction in the dissolution rate. The addition of
methyl cellulose to the dissolution medium was found to delay the theophylline monohydrate growth
and changed the morphology of the monohydrate. The net effect was an increased dissolution rate for
theophylline anhydrate. Our results show that in situ CARS microscopy combined with inline UV absorp-
tion spectroscopy is capable of monitoring oral dosage forms undergoing dissolution and correlating
changes in solid-state form with changes in dissolution rate.
 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license1. Introduction
Active pharmaceutical ingredients (API) commonly exist in var-
ious crystalline forms, known as polymorphs, with different molec-
ular arrangements and/or conformations. Multi-component
crystals, where one or more additional compounds are incorpo-
rated into the crystal lattice, may also be formed and include salts,
co-crystals, and solvates. A widely observed solvate is the hydrate,
where water molecules have been incorporated into the API’s crys-
tal lattice. Single and multi-component API solids may also exist in
a higher energy, disordered amorphous form.
The solid-state form of an API is an important parameter in the
development of oral dosage formulations. It has an effect on the
chemical and physical stability, processibility, solubility, dissolu-tion rate, and potentially bioavailability of the API. In dynamic
environments, solid-state changes in pharmaceutical materials
are common: there have been numerous reports on solid-state
forms undergoing changes during processing [1–3] and storage
and dissolution [4–6].
Solid-state changes that occur during dissolution when a meta-
stable form (higher solubility) converts to a stable form (lower sol-
ubility) through precipitation from a supersaturated solution are
called solvent-mediated phase transformations [7]. The kinetics
of a solvent-mediated phase transformation are determined by
the relative rates of dissolution and growth of the two phases
[7,8]. Solution-mediated transformations of APIs are well docu-
mented. Murphy et al. [5] studied the conversion of carbamazepine
(CBZ) form III to the dihydrate form in samples undergoing disso-
lution testing. They found that the conversion time depended on
grinding and storage conditions of the form III [5]. Savolainen
et al. [9] studied the dissolution of amorphous indomethacin
(IMC) and compared this to the dissolution of a and c forms of
IMC. As expected, they found that the initial intrinsic dissolution
rate for amorphous IMC was faster than for either crystalline form.
However, the dissolution rate decreased as the sample surfaces be-
gan to crystallize to a-IMC during dissolution. Aaltonen et al. [10]
have reported the conversion of theophylline (TP) anhydrate (TPa)
to theophylline monohydrate (TPm) during dissolution testing.
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during dissolution testing have led to investigations into methods
for preventing or reducing such transformations. A number of
studies have found that some excipients are capable of inhibiting
or delaying the hydrate formation. Katzhendler et al. [11] ﬁrst re-
ported hydroxypropylmethylcellulose (HPMC) inhibiting the
transformation of CBZ to CBZ dihydrate on tablets in aqueous
solutions. They suggest that hydroxyl groups from HPMC may at-
tach to CBZ at the site of water binding, thereby inhibiting the
growth of the dihydrate form. More recently, Wikstrom et al.
[12] investigated the effect of pharmaceutical excipients on TPm
formation during wet granulation. They found that the majority
of excipients tested did not change the transformation kinetics
of TP. However, polymeric binders such as methyl cellulose
(MC) and HPMC could signiﬁcantly inhibit the conversion of TPa
to TPm during wet granulation. Wikstrom et al. [12] suggested
that the inhibitory polymers adsorb to fast-growing surfaces of
the hydrate crystal inhibiting crystal growth and causing morpho-
logical changes.
Dissolution testing is an important part of oral solid dosage
form development since the dissolution behavior of a drug is a
key determinant of therapeutic efﬁcacy for many drugs. This is
particularly important for poorly soluble drugs, as drugs must
dissolve ﬁrst before being absorbed [13]. Standard pharmacopoe-
ial methods require the immersion of the drug (e.g., as a compact)
in a ﬂowing dissolution medium with samples of the dissolution
medium being removed over a series of time intervals to be ana-
lyzed for drug concentration in solution using UV absorption
spectroscopy or HPLC [14]. Analyzing solution concentration pro-
vides information about how much drug is dissolved. However, it
does not give any direct information about physical changes on
the surface of the dissolving dosage form, including solid-
state changes, which can affect dissolution behavior. Direct anal-
ysis of the solid dosage form changes during dissolution testing
can therefore provide improved understanding of dissolution
behavior.
In situ analysis of the solid drug or dosage form during disso-
lution testing places a number of restrictions on the suitable ana-
lytical techniques. Firstly, the technique must be nondestructive
to the sample. Secondly, the technique must be able to obtain
data in the presence of dissolution medium with a sufﬁcient tem-
poral resolution (on the order of seconds) to observe rapid
changes in the sample. Finally, the technique must not interfere
with the dissolution process. Common solid-state techniques such
as X-ray powder diffraction (XRPD), scanning electron microscopy
(SEM), near infrared (NIR), and infrared (IR) spectroscopy all have
limiting factors preventing their use in situ for dissolution. The
radiation used in NIR and IR imaging is strongly absorbed by
water limiting their use in aqueous environments [15,16]. Scan-
ning electron microscopy has been used to characterize solid-
state changes on the surfaces of dosage forms after dissolution
[10,17]. X-ray powder diffraction has been used to depth proﬁle
phase changes on samples undergoing dissolution related solid-
state changes [17]. However, both SEM and XRPD are unsuitable
for in situ analysis of dissolution due to sample preparation
requirements. Spontaneous Raman spectroscopy has been shown
to be suitable for in situ analysis of solid-state transformations
during dissolution [9,10]. Spontaneous Raman spectroscopy has
the advantage that it can generate full vibrational spectra in a rel-
atively short period of time. Coupled with a ﬂow through cell and
UV ﬂow through absorption spectroscopy, it has been used in situ
to monitor various solid-state conversions and their effects on
dissolution, including transformation from TPa to TPm, and the
crystallization of amorphous IMC and CBZ. However, spontaneous
Raman spectroscopy gives no spatial information, meaning that it
is not capable of identifying where solid-state conversions areoccurring during dissolution and techniques developed to map
Raman intensity are slow (minutes to hours), precluding in situ
analysis during dissolution testing.
Instead, we use coherent anti-Stokes Raman scattering (CARS)
microscopy as a tool for in situ analysis during dissolution. A
summary of CARS microscopy is provided in [18]. Brieﬂy, CARS
microscopy is capable of rapid spectrally- and spatially-resolved
imaging allowing the visualization of different solid-state forms
of drugs based on their Raman vibrational spectra. A narrowband
CARS setup typically utilizes two synchronized pulsed lasers, one
of which is tuneable in wavelength. The two laser beams are tem-
porally and spatially overlapped before being focused on the sam-
ple. If the frequency difference between the two laser beams
matches a Raman active vibrational mode, an anti-Stokes (blue-
shifted with respect to input beams) signal is produced. Raman
vibrational modes are speciﬁc for compounds or groups of com-
pounds providing chemically speciﬁc images. As the CARS signal
is produced only within the focal volume of the lasers, the process
is inherently confocal, allowing resolution down to the diffraction
limit in three dimensions.
CARS is a third order non-linear optical technique that probes
the same molecular vibrational frequencies as spontaneous Raman
techniques. This means that CARS spectra are comparable to but
not the same as Raman spectra. Coherent Raman techniques such
as CARS have about 100 times faster imaging speed when com-
pared to spontaneous Raman mapping techniques [19]. Spontane-
ous Raman techniques collect information over a wide spectral
range, while narrowband coherent Raman techniques collect infor-
mation from only a single Raman shift. Broadband coherent
Raman techniques are able to probe a wider spectral region
(600–3200 cm1) but with a reduced spectral resolution (about
10 cm1) and a slower imaging speed (50 ms/pixel) when com-
pared to narrowband coherent Raman techniques [20]. As CARS
produces anti-Stokes shifted signal (blueshifted with respect to
excitation pulses), it is free from single photon ﬂuorescence, which
hampers spontaneous Raman measurements. Unlike spontaneous
Raman where the anti-Stokes scattering is much weaker than the
Stokes scattering, the CARS process actively drives molecules into
a speciﬁc vibrational mode and therefore generates signiﬁcantly
more signal with reduced temperature sensitivity.
CARS microscopy has been used to image a few pharmaceutical
systems during drug release. Kang et al. [21–23] published work
where they imaged in situ release of paclitaxel from polymeric
ﬁlms in a static medium (phosphate buffer) using CARS micros-
copy. In the ﬁrst work focusing on orally administered drugs and
dosage forms, Windbergs et al. [24] and Jurna et al. [25] used CARS
microscopy to image the distribution of TP in lipid dosage forms
and monitored the release of TP during dissolution in a ﬂow
through cell setup. They were able to image both drug release
and conversion from TPa to TPm in real time.
We have developed a new analytical technique to record the
dissolved drug concentration and simultaneously monitor solid-
state changes on the surface of the oral solid dosage form undergo-
ing dissolution. Furthermore, we have applied hyperspectral CARS
microscopy for improved solid-state form characterization. We
illustrate the use of these techniques using the model drug theoph-
ylline (TP) in different dissolution media.
2. Materials and methods
2.1. Materials
USP grade theophylline (TP, 1,3-dimethyl-7H-purine-2,6-dione)
anhydrate and monohydrate were gifted from BASF (Ludwigsha-
fen, Germany). Methyl cellulose (MC) (Methocel A4C premium)
was gifted from Colorcon GmbH (Idstein, Germany).
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Weighed amounts of TPa and TPm (0.49 g) were directly com-
pressed using a force feed tablet press (IMA Kilian Pressima, Italy).
The upper punch had a pre-compression height of 9.22 mm and a
ﬁnal compression height of 3.02 mm using a compaction force of
about 13 kN, resulting in compacts which had a diameter of
12.02 mm and a thickness of about 3 mm. The compression did
not result in changes in the solid-state form, which we conﬁrmed
using hyperspectral CARS microscopy.Fig. 2. Hyperspectral imaging process illustrated using a sample with two different
types of plastic beads (reproduced from [26] with permission of Wiley). (For
interpretation of the references to color in this ﬁgure legend, the reader is referred
to the web version of this article.)2.2. Methods
2.2.1. CARS microscopy
The CARS microscopy system is illustrated in Fig. 1 and is de-
scribed in more detail elsewhere [26]. A Nd:YVO4 picosecond
pulsed laser (Coherent Inc., USA) operating at a fundamental wave-
length of 1064 nm was frequency doubled to pump an optical
parametric oscillator (OPO) (APE Berlin GmbH, Germany), which
produced two dependently tunable laser beams. The fundamental
laser beam was combined with the signal beam from the OPO and
directed into an inverted laser-scanning microscope (Olympus
IX71/FV300, Japan) where they were focused onto the sample
using a 20/0.5 NA objective. The backscattered CARS signal was
collected by the focusing objective, spectrally ﬁltered to remove
the excitation wavelengths, and detected with a photomultiplier
tube (Hamamatsu R3896, Japan). The CARS microscope system
had an axial spatial resolution of about 10 lm and a lateral spatial
resolution of about 1 lm.2.2.2. Hyperspectral CARS imaging
Hyperspectral CARS imaging provides a method to rapidly and
visually conﬁrm the solid-state form on the surface of an oral dos-
age form, both pre- and post-dissolution. Hyperspectral CARS
images were obtained by rapidly imaging the sample while slowly
sweeping the wavelength of the OPO in discrete steps, so that each
frame in the image stack corresponds to a different vibrational fre-
quency [26]. A color look up table was then applied to the image
stack, with a separate color applied to each frame in the image.
Finally, the frames were projected together, resulting in a single
two-dimensional image wherein each material appears with a un-
ique color. This process is illustrated as a diagram in Fig. 2. In this
study, 512  512 pixel hyperspectral images were collected over a
range of 100 cm1 with each hyperspectral image taking approxi-
mately 2 min to record. CARS spectra shown in this article are pixel
intensity proﬁles across the vibrational frequencies and were
extracted from the hyperspectral image data. Further information
about the collection of CARS spectra can be found in Garbacik
et al. [26].Fig. 1. Schematic illustrating CARS for dissolution setup. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of
this article.)2.2.3. In situ CARS dissolution imaging
In situ CARS images (512  512 pixels) covering 350  350 lm
were recorded every 1.12 s (roughly 4.3 ls/pixel dwell time) for
the duration of the dissolution experiments (15 min). All in situ
CARS images recorded during dissolution testing were recorded
at 2952 cm1 and were false colored green. This peak has been as-
signed to antisymmetric C–H stretching in the methyl groups [27]
and provided a strong CARS signal for both TPa and TPm.2.2.4. Dissolution
A deuterium light source (DT-MINI-2, Ocean Optics, The Neth-
erlands) was connected by an optical ﬁber to a Z-shaped ﬂow cell
(FIA-Z-SMA, Ocean Optics, The Netherlands) with a 10 mm path
length An optical ﬁber connected the Z-shaped ﬂow cell to a CCD
spectrometer (USB2000+, Ocean Optics, The Netherlands). Open
loop channel ﬂow through intrinsic dissolution was conducted
using a peristaltic pump (Reglo, ISMATEC, Germany), which
pumped dissolution medium (distilled water or methyl cellulose
0.45% w/v) through the custom built CARS microscopy dissolution
ﬂow cell and through the Z-shaped UV ﬂow cell at a rate of 5 mL/
min. UV spectra were collected at 290 nm every 30 s. Dissolution
was conducted multiple times on each sample to check for
consistency.3. Results and discussion
3.1. Hyperspectral CARS analysis of TPa and TPm
CARS spectra of the C–H stretch region were collected prior to
dissolution experiments on pure TPa and TPm to identify an
appropriate vibrational frequency at which to record CARS images
during dissolution experiments and for comparison to the before
and after dissolution hyperspectral scans of the compacts. The
C–H stretch region was chosen as TP has an intense signal in that
region for both solid-state forms (Fig. 3). Both TPa and TPm fea-
tured a peak at around 2950 cm1, which has been assigned to
antisymmetric C–H stretching in the two methyl groups (masC(1,3)-
H3) [27]. There was a peak shift between the two forms in the C–
H stretching region of the spectra at a higher Raman shift, with
the TPa peak at around 3120 cm1 and the TPm peak at around
3105 cm1. This peak has been assigned to the imidazole ring
Fig. 3. CARS C–H stretch region spectra between 2900 and 3200 cm1 for TPa (black
line), and TPm (red dashed line). (For interpretation of the references to color in this
ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 5. CARS spectra between 3050 and 3150 cm1 for TPa compacts before
dissolution (black line) and after dissolution where water was used as dissolution
medium (red dashed line). (For interpretation of the references to color in this
ﬁgure legend, the reader is referred to the web version of this article.)
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intermolecular hydrogen bonding in the TPm form [27,28]. The
peak shift allowed us to visualize the change in anhydrate to
monohydrate using hyperspectral imaging. However, the shifting
peak was not suitable for single-frequency CARS dissolution imag-
ing because it was not possible to simultaneously image the TPm
crystal growth on the surface of a TPa compact.
Since both TPa and TPm produce a strong signal at 2952 cm1,
single-frequency CARS images were recorded at this Raman shift
during dissolution experiments to allow visualization of both TPa
and TPm simultaneously. Additionally, at 2952 cm1, there is very
little interference due to the presence of water.
Hyperspectral images were recorded before and after dissolu-
tion experiments to allow a rapid visual conﬁrmation of the solid-
state conversion on the surface of the compact which would be
evident as a change in color. Fig. 4A shows the pre-dissolution
hyperspectral image for a TPa compact, while Fig. 4B shows the
post-dissolution hyperspectral image for the same TPa compact
recorded after the duration of one dissolution experiment
(15 min) using water as dissolution medium. The color change
between Fig. 4A and B is due to the mC(8)–H peak shift in CARS
spectra, indicating that the TP on the surface has converted to
TPm form.
The CARS spectra were collected before and after each dissolu-
tion experiment for comparison with the reference spectra (Fig. 3)Fig. 4. Hyperspectral CARS image recorded between 3050 and 3150 cm1 of a
TPa compact before (A) and after (B) dissolution where water was used as
dissolution medium. (For interpretation of the references to color in this ﬁgure
legend, the reader is referred to the web version of this article.)and to conﬁrm the solid-state conversion observed in the dissolu-
tion images. Fig. 5 shows the pre-dissolution (black line) and post-
dissolution (red dashed line) CARS spectra for a TPa compact after
dissolution using water as the dissolution medium. The CARS spec-
tra conﬁrm the observed shift in the peak from around 3120 cm1
(before) to 3105 cm1 (after), indicating the conversion from TPa to
TPm on the surface of the compact.3.2. In situ analysis of TP during dissolution testing
3.2.1. Theophylline in water dissolution
Single-frequency CARS images (512  512 pixels) were re-
corded at 2952 cm1 approximately every second for the duration
of the dissolution experiments (15 min). Fig. 6 shows snapshots of
the dissolution imaging from dissolution conducted using water as
dissolution medium. From Fig. 6, it is apparent that the TPm nucle-
ation and crystal growth begin almost immediately after the begin-
ning of the dissolution experiment with TPm crystals (needle
shape) growing outwards from two nuclei on the surface of the
compact. After 2 min, about half of the ﬁeld of view is covered in
TPm crystals, and it appears that most of the ﬁeld of view is com-
pletely covered in TPm after about 4 min.
Ultraviolet spectra were collected every 30 s during the dissolu-
tion experiment to determine the dissolution rate proﬁles for TPa
and TPm in our channel ﬂow cell system. Fig. 7 shows the dissolu-
tion proﬁles for TPa (solid lines) and TPm compacts (dashed lines).
From Fig. 7, it can be seen that TPa initially increases to peak values
of between 150 and 190 lg/mL, while the TPm reaches concentra-
tions of between 70 and 80 lg/mL. Subsequently, there is a sharp
drop in the ﬁrst few minutes of the TPa dissolution that is not seen
for the TPm dissolution. This change in dissolution behavior is due
to a solvent-mediated transformation wherein the dissolving TPa
(solubility 12 mg/mL at 25 C [29]) reaches supersaturation which
causes precipitation and growth of the more stable but less soluble
TPm (solubility 6 mg/mL at 25 C [29]) crystals that grow on the
surface of the TPa compacts during dissolution. The surface growth
of TPm on TPa samples undergoing dissolution has also been ob-
served in other studies, using ofﬂine XRPD analysis [17] and inline
spontaneous Raman spectroscopy [10,30].
The UV data shown in Fig. 7 correlate well with the CARS
images (Fig. 6) that were recorded during the dissolution
Fig. 6. Single-frequency CARS images (2952 cm1) of TPm crystals growing on the surface of a TPa compact undergoing dissolution using water as the dissolution medium.
Still images from a dissolution video show progressive crystal growth. Video is available in Supplementary material. (For interpretation of the references to color in this ﬁgure
legend, the reader is referred to the web version of this article.)
Fig. 7. Channel ﬂow through cell dissolution proﬁles for TPa (solid lines) and TPm
(dashed lines) compacts using water as dissolution medium. (For interpretation of
the references to color in this ﬁgure legend, the reader is referred to the web version
of this article.)
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related to about half of the microscope ﬁeld of view covered in TPm
needle-shaped crystals. After about 5 min, the dissolution rate
reached a plateau at the same time the crystal growth appeared
to completely cover the ﬁeld of view. Fig. 7 shows that the TPm
dissolution rate quickly reached a steady state after around
1 min and remained there for the duration of the experiment.
The steady-state dissolution rates were calculated to be
360 ± 37 lg/min/cm2 and 320 ± 12 lg/min/cm2 for the compacts
prepared from TPa and TPm, respectively. The slightly higher disso-
lution rate (not statistically signiﬁcant) for the compacts originally
composed of TPa after surface conversion to TPm can be attributed
to the TPm needle growth resulting in a larger surface area.3.2.2. Theophylline in methyl cellulose solution dissolution
In situ CARS dissolution imaging identiﬁed delayed TPm crystal
growth on the surface of TPa compacts undergoing dissolution
using a MC solution (0.45% w/v) as the dissolution medium.
Fig. 8 shows in situ single-frequency CARS snapshots taken from
a dissolution video. The TPm crystal growth was delayed as it
was ﬁrst observed after approximately 300 s (5 min), and the sur-
face coverage with TPm was incomplete after the duration of the
experiment (15 min). Additionally, the TPm crystals were of a dif-
ferent morphology than previously seen when using water as the
dissolution medium. Instead of the thin needle-like structure seen
growing in water, there was a broad almost sheet-like growth
along the surface of the compact.
The delayed onset of crystal growth and different morphologies
suggests that the polymer affects both nucleation and crystal
growth. It has been suggested that the polymer adsorbs to the sur-
face of the TPa particles, and this leads to inhibition of heteroge-
neous nucleation, while the changed crystal morphology is likely
to be due to preferential adsorption to speciﬁc crystal faces of
TPm, which, in turn, affects their relative growth rates [12].
The delayed TPm crystal growth seen in the CARS dissolution
imaging (Fig. 8) was expected to affect the TPa dissolution rate
and Fig. 9 shows that this was the case. Fig. 9 shows the dissolution
proﬁles for TPa and TPm compacts undergoing dissolution using
MC solution as the dissolution medium. From Fig. 9 it can be seen
that the characteristic decrease in dissolution rate associated with
TPm growth on the surface of TPa compacts (Fig. 7) is no longer
seen. Instead the TPa compacts reach a concentration of about
150 lg/mL and remain there for the duration of the experiment.
The dissolution behavior of the TPm compacts appear minimally
affected by the use of the MC dissolution medium as they reach
a concentration of about 80 lg/mL and remain there for the dura-
tion of the experiment. This concentration is the same as was ob-
served for water without the polymer, revealing that the
solubility of the drug is not affected by the polymer in solution,
and therefore the different dissolution proﬁles obtained with and
without polymer solution are not solubility mediated.
Fig. 8. Single-frequency CARS images (2952 cm1) of TPm crystals growing on the surface of a TPa compact undergoing dissolution using MC solution (0.45% w/v) as
dissolution medium. Still images from a dissolution video show delayed crystal growth and different crystal morphologies. Video is available in Supplementary material. (For
interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 9. Channel ﬂow through cell dissolution proﬁles for TPa (solid lines) and TPm
(dashed lines) using MC solution as dissolution medium. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of
this article.)
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be 700 ± 130 lg/min/cm2 and 350 ± 40 lg/min/cm2 for the com-
pacts prepared from TPa and TPm respectively (assuming both
compacts had a perfectly planar surface). Since the solubility of
the TPa is twice that of TPm in water at 25 C [29], a two-fold in-
crease in the dissolution rate of the compact prepared from TPa
would theoretically only be expected if there were no conversion
to the monohydrate. However, an increase in surface area of the
compacts prepared from TPa after TPm formation was observed
in water which affected the dissolution behavior, and therefore a
surface area increase can also be expected to affect the dissolution
proﬁles in the polymer solution. Additionally, from Fig. 9 there are
noticeable ﬂuctuations in the steady-state concentrations (whencompared to Fig. 7) of both TPa and TPm this is attributed to bub-
bles in the dissolution medium not removed by sonication.
The inherent confocality, chemical speciﬁcity, and speed
provided by CARS microscopy increases the spatial and chemical
resolution of the system providing advantages over existing
approaches including traditional optical microscopy and Raman
microscopy based on spontaneous Raman scattering. The biggest
advantage when compared to traditional optical microscopy is
the fact that the detected signal is generated when the excitation
beams match the Raman vibrational mode for the chemical of
interest this provides chemical selectivity. If the excitation laser
frequencies are incorrect or the sample is the wrong chemical then
no resonant signal is generated. The inherent confocal nature
means that the morphological information is resolved to approxi-
mately 10 lm in the depth direction, a resolution that is not ob-
tained with traditional optical microscopy.4. Conclusions
We used CARS microscopy to image in situ solid-state conver-
sions of samples during dissolution in real time. The combination
of CARS microscopy with ﬂow through UV absorbance spectros-
copy allowed us to correlate the visualized polymorphic conver-
sion with changes in dissolution rates. Additionally the inhibition
of TPm crystal growth due to the presence of MC was correlated
with changes in dissolution rate for TPa compacts. Hyperspectral
CARS microscopy provided a rapid visual technique to conﬁrm
the polymorphic conversion that occurred during dissolution. The
combination of the rapid analysis and chemical selectivity of CARS
and hyperspectral CARS with UV absorption spectroscopy has the
potential to allow improved characterization of solid dosage forms
undergoing dissolution. CARS with UV absorption spectroscopy al-
lows further in depth analysis on dosage forms exhibiting unex-
pected dissolution proﬁles, including failed dissolution tests.
Improved characterization of solid dosage forms undergoing disso-
A. Fussell et al. / European Journal of Pharmaceutics and Biopharmaceutics 85 (2013) 1141–1147 1147lution will help in the development of formulations where dissolu-
tion proﬁles are especially important. Formulations such as those
containing a poorly soluble APIs and controlled release formula-
tions, where bioavailability is dissolution- or release-rate limited
will beneﬁt from improved characterization.
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